VYNE Therapeutics Inc.

VYNE Therapeutics Inc.

YARW · Nasdaq

VYNE Therapeutics Inc. (YARW) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for VYNE Therapeutics Inc. in 2026. The next earnings report is expected on November 5, 2026.

Earnings calendar

Next earnings date

05 Nov 2026

In 76 days

EPS estimate

-16.00

Revenue estimate

200.0K

Past earnings

13 Aug 2026
EPS actual
-2.14 (+80.5%)
estimate -11.00
Revenue actual
—
estimate 200.0K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
18 May 2026
EPS actual
—
estimate -0.18
Revenue actual
—
estimate 200.0K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
15 May 2026
EPS actual
-32.50 (-261.1%)
estimate -9.00
Revenue actual
—
estimate 200.0K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
13 May 2026
EPS actual
—
estimate -0.18
Revenue actual
—
estimate 200.0K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
27 Feb 2026
EPS actual
—
estimate -0.23
Revenue actual
—
estimate 175.0K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
06 Nov 2025
EPS actual
-0.17 (+1.9%)
estimate -0.17
Revenue actual
169.0K (+35.2%)
estimate 125.0K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Yarrow Bioscience beat consensus estimates on EPS, delivering a loss of $2.14 versus an estimated loss of $11, while revenue was not disclosed against an estimate of $200 thousand. In the prior quarter, EPS missed expectations and revenue was likewise not reported relative to the $200 thousand estimate.

Dividend calendar

Next ex-dividend

—

Not scheduled

Next payment

—

Not scheduled

Dividend amount

—

Not available

Past dividends

Ex-dividend Payment Amount
24 Jul 2026 23 Jul 2026 0.40

EPS (Earnings Per Share)

Revenue

Dividend per share

Company profile

VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
David T. Domzalski
Employees
10
IPO date
25 Jan 2018
ISIN
US92941V3087
Website
vynetherapeutics.com

Frequently asked questions

When does VYNE Therapeutics Inc. (YARW) next report earnings?

VYNE Therapeutics Inc. (YARW) is scheduled to report earnings on November 5, 2026.

What was VYNE Therapeutics Inc.'s most recent earnings date?

VYNE Therapeutics Inc. (YARW) last reported earnings on August 13, 2026.

Where is VYNE Therapeutics Inc. stock listed?

VYNE Therapeutics Inc. (YARW) is listed on Nasdaq.